查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1475205

全球风湿病治疗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Rheumatology Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

全球风湿病治疗市场需求预计将从 2023 年的 492.1 亿美元达到 2032 年近 651.1 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 3.16%。

风湿病治疗是指用于管理和治疗风湿性疾病的药物和治疗，包括影响关节、肌肉、骨骼和结缔组织的自体免疫疾病、发炎和退化性疾病。这些疗法旨在减轻疼痛、发炎、僵硬和关节损伤，减缓疾病进展，改善身体功能，并提高风湿性疾病患者的生活水平。

市场动态

类风湿性关节炎(RA)、系统性红斑狼疮(SLE)、骨关节炎(OA) 以及其他自体免疫和发炎性疾病的发生率不断上升，推动了对风湿病治疗的需求，因为患者寻求有效的治疗方法来缓解症状、减缓疾病进展并增强疗效。随着人口老化、遗传倾向和环境因素造成全球风湿病负担，人们越来越需要针对潜在疾病机制、调节免疫反应并恢復受影响个体的组织稳态的创新疗法。

此外，生物製药研究、免疫学和分子生物学的进步使得新型生物製剂、小分子抑制剂和标靶疗法的开发成为可能，与传统的缓解疾病的抗风湿药物 (DMARD) 和非类固醇类抗炎药（NSAID）。此外，随着製药公司、生物技术新创公司和学术研究人员合作识别患者亚群、对疾病表型进行分层并开发个人化治疗演算法，以优化治疗结果并最大限度地减少风险，对精准医学、生物标记发现和药物基因组学的日益重视推动了风湿病治疗市场的创新 不利影响。

此外，风湿病领域越来越多地采用生物相似药、生物优越剂和下一代疗法，推动了市场竞争、定价动态和创新治疗的获取，为药物开发商、医疗保健提供者和患者创造了机会和挑战。然而，来自生物相似药替代品和监管障碍的日益激烈的竞争可能会挑战未来几年风湿病治疗市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球风湿病治疗市场的各个细分市场进行了包容性评估。风湿病治疗产业的成长和趋势为这项研究提供了整体方法。

市场区隔

风湿病治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按药物类别

  • 疾病修饰抗风湿药物 (Dmards)（合成疾病修饰抗风湿药物、生物疾病修饰抗风湿药物）
  • 非类固醇类抗发炎药（Nsaids）
  • 皮质类固醇
  • 降尿酸药物
  • 其他的

按疾病适应症

  • 类风湿关节炎
  • 骨关节炎
  • 痛风
  • 银屑病关节炎
  • 僵直性脊椎炎
  • 其他的

依给药途径

  • 肠外途径
  • 口头途径
  • 专题

按配销通路

  • 医院药房
  • 零售药房
  • 网路药房

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲风湿病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。风湿病治疗市场的主要参与者包括默克公司、艾伯维公司、百时美施贵宝公司、辉瑞公司、武田製药有限公司、安进公司、基因泰克公司、诺华公司、强生创新医学、F. Hoffmann -La Roche AG、赛诺菲。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：风湿病治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按药品类别分類的市场吸引力分析
    • 依疾病适应症进行的市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 按配销通路分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球风湿病治疗市场分析：依药物类别

  • 按药物类别概述
  • 历史和预测数据
  • 按药物类别分析
  • 疾病修饰抗风湿药物 (DMARD)（合成疾病修饰抗风湿药物、生物疾病修饰抗风湿药物）
  • 非类固醇类抗发炎药 (NSAID)
  • 皮质类固醇
  • 降尿酸药物
  • 其他的

第 6 章：全球风湿病治疗市场分析：依疾病适应症

  • 按疾病适应症概述
  • 历史和预测数据
  • 按疾病指征分析
  • 类风湿关节炎
  • 骨关节炎
  • 痛风
  • 银屑病关节炎
  • 僵直性脊椎炎
  • 其他的

第 7 章：全球风湿病治疗市场分析：依给药途径

  • 依给药途径概述
  • 历史和预测数据
  • 依给药途径分析
  • 肠外途径
  • 口头途径
  • 专题

第 8 章：全球风湿病治疗市场分析：按分销管道

  • 配销通路概述
  • 历史和预测数据
  • 按配销通路分析
  • 医院药房
  • 零售药房
  • 网路药房

第 9 章：全球风湿病治疗市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：风湿病治疗公司的竞争格局

  • 风湿病治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Merck & Co. Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • AbbVie Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Bristol-Myers Squibb Company
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Pfizer Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Takeda Pharmaceutical Company Limited
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Amgen Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Genentech Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Novartis AG
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Johnson & Johnson Innovative Medicine
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • F. Hoffmann-La Roche AG
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Sanofi
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR112114346

The global demand for Rheumatology Therapeutics Market is presumed to reach the market size of nearly USD 65.11 Billion by 2032 from USD 49.21 Billion in 2023 with a CAGR of 3.16% under the study period 2024 - 2032.

Rheumatology therapeutics refers to medications and treatments for managing and treating rheumatic diseases, encompassing autoimmune, inflammatory, and degenerative conditions affecting the joints, muscles, bones, and connective tissues. These therapeutics aim to alleviate pain, inflammation, stiffness, and joint damage, slow disease progression, improve physical function, and improve the standard of living for patients with rheumatic disorders.

MARKET DYNAMICS

The rising incidence of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), osteoarthritis (OA), and other autoimmune and inflammatory conditions drives the demand for rheumatology therapeutics as patients seek effective treatments that alleviate symptoms, slow disease progression, and enhance the quality of life. With aging populations, genetic predisposition, and environmental factors contributing to the global burden of rheumatic diseases, there is a growing need for innovative therapeutics that target underlying disease mechanisms, modulate immune responses, and restore tissue homeostasis in affected individuals.

Additionally, advancements in biopharmaceutical research, immunology, and molecular biology enable the development of novel biologics, small molecule inhibitors, and targeted therapies that offer improved efficacy, safety, and tolerability profiles compared to conventional disease-modifying anti-rheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs). Moreover, the increasing emphasis on precision medicine, biomarker discovery, and pharmacogenomics drives rheumatology therapeutics market innovation as pharmaceutical companies, biotech startups, and academic researchers collaborate to identify patient subgroups, stratify disease phenotypes, and develop personalized treatment algorithms that optimize therapeutic outcomes and minimize adverse effects.

Furthermore, the growing adoption of biosimilars, biosuperiors, and next-generation therapeutics in rheumatology drives market competition, pricing dynamics, and access to innovative treatments, creating opportunities and challenges for drug developers, healthcare providers, and patients. However, increasing competition from biosimilar alternatives and regulatory hurdles may challenge the rheumatology therapeutics market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rheumatology therapeutics. The growth and trends of rheumatology therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the rheumatology therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Disease Modifying Anti-Rheumatic Drugs (Dmards) (Synthetic Disease Modifying Anti-Rheumatic Drugs, Biologic Disease Modifying Anti-Rheumatic Drugs)
  • Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

By Disease Indication

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Others

By Route Of Administration

  • Parenteral Route
  • Oral Route
  • Topical

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Rheumatology Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Rheumatology Therapeutics market include Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Amgen, Inc., Genentech, Inc., Novartis AG, Johnson & Johnson Innovative Medicine, F. Hoffmann-La Roche AG, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. RHEUMATOLOGY THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Disease Indication
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

  • 5.1. Overview By Drug Class
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Class
  • 5.4. Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Historic and Forecast Sales By Regions
  • 5.5. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Historic and Forecast Sales By Regions
  • 5.6. Corticosteroids Historic and Forecast Sales By Regions
  • 5.7. Uric Acid Drugs Historic and Forecast Sales By Regions
  • 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISEASE INDICATION

  • 6.1. Overview By Disease Indication
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Disease Indication
  • 6.4. Rheumatoid Arthritis Historic and Forecast Sales By Regions
  • 6.5. Osteoarthritis Historic and Forecast Sales By Regions
  • 6.6. Gout Historic and Forecast Sales By Regions
  • 6.7. Psoriatic Arthritis Historic and Forecast Sales By Regions
  • 6.8. Ankylosing Spondylitis Historic and Forecast Sales By Regions
  • 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Route of Administration
  • 7.4. Parenteral Route Historic and Forecast Sales By Regions
  • 7.5. Oral Route Historic and Forecast Sales By Regions
  • 7.6. Topical Historic and Forecast Sales By Regions

8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1. Overview By Distribution Channel
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Distribution Channel
  • 8.4. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 8.5. Retail Pharmacy Historic and Forecast Sales By Regions
  • 8.6. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE RHEUMATOLOGY THERAPEUTICS COMPANIES

  • 10.1. Rheumatology Therapeutics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF RHEUMATOLOGY THERAPEUTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Merck & Co. Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. AbbVie Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Bristol-Myers Squibb Company
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Pfizer Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Takeda Pharmaceutical Company Limited
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Amgen Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Genentech Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Novartis AG
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Johnson & Johnson Innovative Medicine
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. F. Hoffmann-La Roche AG
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Sanofi
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class (USD MN)
  • Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Market Sales By Geography (USD MN)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Uric Acid Drugs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Disease Indication (USD MN)
  • Rheumatoid Arthritis Market Sales By Geography (USD MN)
  • Osteoarthritis Market Sales By Geography (USD MN)
  • Gout Market Sales By Geography (USD MN)
  • Psoriatic Arthritis Market Sales By Geography (USD MN)
  • Ankylosing Spondylitis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Parenteral Route Market Sales By Geography (USD MN)
  • Oral Route Market Sales By Geography (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Rheumatology Therapeutics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Rheumatology Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Rheumatology Therapeutics Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Disease Indication
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class (USD MN)
  • Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Market Sales By Geography (USD MN)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Uric Acid Drugs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Disease Indication (USD MN)
  • Rheumatoid Arthritis Market Sales By Geography (USD MN)
  • Osteoarthritis Market Sales By Geography (USD MN)
  • Gout Market Sales By Geography (USD MN)
  • Psoriatic Arthritis Market Sales By Geography (USD MN)
  • Ankylosing Spondylitis Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Parenteral Route Market Sales By Geography (USD MN)
  • Oral Route Market Sales By Geography (USD MN)
  • Topical Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.